1
|
Zheng J, Zhang W, Xu R, Liu L. The role of adiponectin and its receptor signaling in ocular inflammation-associated diseases. Biochem Biophys Res Commun 2024; 717:150041. [PMID: 38710142 DOI: 10.1016/j.bbrc.2024.150041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Revised: 04/13/2024] [Accepted: 04/29/2024] [Indexed: 05/08/2024]
Abstract
Ocular inflammation-associated diseases are leading causes of global visual impairment, with limited treatment options. Adiponectin, a hormone primarily secreted by adipose tissue, binds to its receptors, which are widely distributed throughout the body, exerting powerful physiological regulatory effects. The protective role of adiponectin in various inflammatory diseases has gained increasing attention in recent years. Previous studies have confirmed the presence of adiponectin and its receptors in the eyes. Furthermore, adiponectin and its analogs have shown potential as novel drugs for the treatment of inflammatory eye diseases. This article summarizes the evidence for the interplay between adiponectin and inflammatory eye diseases and provides new perspectives on the diagnostic and therapeutic possibilities of adiponectin.
Collapse
Affiliation(s)
- Jing Zheng
- Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China; Department of Optometry and Visual Science, West China Hospital, Sichuan University, Chengdu, China
| | - Wenqiu Zhang
- Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China; Department of Optometry and Visual Science, West China Hospital, Sichuan University, Chengdu, China
| | - Ran Xu
- Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China; Department of Optometry and Visual Science, West China Hospital, Sichuan University, Chengdu, China
| | - Longqian Liu
- Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China; Department of Optometry and Visual Science, West China Hospital, Sichuan University, Chengdu, China.
| |
Collapse
|
2
|
Wang Y, Shi S, Zhang L, Wang S, Qin H, Wei Y, Wu X, Zhang M. Imatinib@glycymicelles entrapped in hydrogel: preparation, characterization, and therapeutic effect on corneal alkali burn in mice. Drug Deliv Transl Res 2024:10.1007/s13346-024-01570-5. [PMID: 38494558 DOI: 10.1007/s13346-024-01570-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/06/2024] [Indexed: 03/19/2024]
Abstract
Imatinib (IMB) is a type of tyrosine kinase inhibitor with great application potential for inhibiting corneal neovascularization (CNV), but its poor water solubility limits its application in eye disease treatment. In this study, novel IMB@glycymicelles entrapped in hydrogel (called IMB@glycymicelle-hydrogel) were prepared, characterized, and evaluated for their therapeutic effects on corneal alkali burn in mice. Imatinib could be successfully loaded in glycymicelles using glycyrrhizin as a nanocarrier with an optimized weight ratio of IMB:nanocarrier. The apparent solubility of IMB was significantly improved from 61.69 ± 5.55 μg/mL to bare IMB to 359,967.62 ± 20,059.42 μg/mL to IMB@glycymicelles. Then, the IMB@glycymicelles were entrapped in hydrogel fabricated with hydroxypropyl methylcellulose and sodium hyaluronate (HA) to prolong retention time on the ocular surface. Rabbit eye tolerance tests showed that IMB@glycymicelle-hydrogel possessed good ocular safety profiles. In a mouse model of corneal alkali burns, the topical administration of IMB@glycymicelle-hydrogel showed strong efficacy by prompting corneal wound healing, recovering corneal sensitivity, relieving corneal opacities, and inhibiting CNV, and these efficacy evaluation parameters were better than those of the positive drug HA. Overall, these results demonstrated that IMB@glycymicelle-hydrogel may be a promising candidate for the effective treatment of alkali ocular damage.
Collapse
Affiliation(s)
- Yanan Wang
- College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China
- Deparment of Pathology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
| | - Shaohua Shi
- College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China
| | - Ling Zhang
- Qingdao Women and Children's Hospital, Qingdao, China
| | - Songtao Wang
- College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China
| | - Hongqing Qin
- College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China
| | - Yanjun Wei
- College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China
- Viwit Pharmaceutical Co., Ltd. Zaozhuang, Shandong, China
| | - Xianggen Wu
- College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China.
- Viwit Pharmaceutical Co., Ltd. Zaozhuang, Shandong, China.
| | - Mengmeng Zhang
- Deparment of Pathology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
| |
Collapse
|
3
|
Desjardins P, Berthiaume R, Couture C, Le-Bel G, Roy V, Gros-Louis F, Moulin VJ, Proulx S, Chemtob S, Germain L, Guérin SL. Impact of Exosomes Released by Different Corneal Cell Types on the Wound Healing Properties of Human Corneal Epithelial Cells. Int J Mol Sci 2022; 23:12201. [PMID: 36293057 PMCID: PMC9602716 DOI: 10.3390/ijms232012201] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Revised: 10/05/2022] [Accepted: 10/06/2022] [Indexed: 09/26/2023] Open
Abstract
Corneal wound healing involves communication between the different cell types that constitute the three cellular layers of the cornea (epithelium, stroma and endothelium), a process ensured in part by a category of extracellular vesicles called exosomes. In the present study, we isolated exosomes released by primary cultured human corneal epithelial cells (hCECs), corneal fibroblasts (hCFs) and corneal endothelial cells (hCEnCs) and determined whether they have wound healing characteristics of their own and to which point they modify the genetic and proteomic pattern of these cell types. Exosomes released by all three cell types significantly accelerated wound closure of scratch-wounded hCECs in vitro compared to controls (without exosomes). Profiling of activated kinases revealed that exosomes from human corneal cells caused the activation of signal transduction mediators that belong to the HSP27, STAT, β-catenin, GSK-3β and p38 pathways. Most of all, data from gene profiling analyses indicated that exosomes, irrespective of their cellular origin, alter a restricted subset of genes that are completely different between each targeted cell type (hCECs, hCFS, hCEnCs). Analysis of the genes specifically differentially regulated for a given cell-type in the microarray data using the Ingenuity Pathway Analysis (IPA) software revealed that the mean gene expression profile of hCECs cultured in the presence of exosomes would likely promote cell proliferation and migration whereas it would reduce differentiation when compared to control cells. Collectively, our findings represent a conceptual advance in understanding the mechanisms of corneal wound repair that may ultimately open new avenues for the development of novel therapeutic approaches to improve closure of corneal wounds.
Collapse
Affiliation(s)
- Pascale Desjardins
- Regenerative Medicine Division of the Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada
- Centre Universitaire d’Ophtalmologie (CUO)-Recherche, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1J 1Z4, Canada
- Centre de Recherche en Organogénèse Expérimentale de l’Université Laval/LOEX, Hôpital Enfant-Jésus, 1401 18e Rue, Québec, QC G1V 0A6, Canada
- Département d’Ophtalmologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
- Département de Chirurgie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
| | - Rébecca Berthiaume
- Regenerative Medicine Division of the Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada
- Centre Universitaire d’Ophtalmologie (CUO)-Recherche, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1J 1Z4, Canada
- Centre de Recherche en Organogénèse Expérimentale de l’Université Laval/LOEX, Hôpital Enfant-Jésus, 1401 18e Rue, Québec, QC G1V 0A6, Canada
- Département d’Ophtalmologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
| | - Camille Couture
- Regenerative Medicine Division of the Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada
- Centre Universitaire d’Ophtalmologie (CUO)-Recherche, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1J 1Z4, Canada
- Centre de Recherche en Organogénèse Expérimentale de l’Université Laval/LOEX, Hôpital Enfant-Jésus, 1401 18e Rue, Québec, QC G1V 0A6, Canada
- Département d’Ophtalmologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
- Département de Chirurgie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
| | - Gaëtan Le-Bel
- Regenerative Medicine Division of the Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada
- Centre Universitaire d’Ophtalmologie (CUO)-Recherche, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1J 1Z4, Canada
- Centre de Recherche en Organogénèse Expérimentale de l’Université Laval/LOEX, Hôpital Enfant-Jésus, 1401 18e Rue, Québec, QC G1V 0A6, Canada
- Département d’Ophtalmologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
- Département de Chirurgie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
| | - Vincent Roy
- Regenerative Medicine Division of the Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada
- Centre de Recherche en Organogénèse Expérimentale de l’Université Laval/LOEX, Hôpital Enfant-Jésus, 1401 18e Rue, Québec, QC G1V 0A6, Canada
- Département de Chirurgie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
| | - François Gros-Louis
- Regenerative Medicine Division of the Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada
- Centre de Recherche en Organogénèse Expérimentale de l’Université Laval/LOEX, Hôpital Enfant-Jésus, 1401 18e Rue, Québec, QC G1V 0A6, Canada
- Département de Chirurgie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
| | - Véronique J. Moulin
- Regenerative Medicine Division of the Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada
- Centre de Recherche en Organogénèse Expérimentale de l’Université Laval/LOEX, Hôpital Enfant-Jésus, 1401 18e Rue, Québec, QC G1V 0A6, Canada
- Département de Chirurgie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
| | - Stéphanie Proulx
- Regenerative Medicine Division of the Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada
- Centre Universitaire d’Ophtalmologie (CUO)-Recherche, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1J 1Z4, Canada
- Centre de Recherche en Organogénèse Expérimentale de l’Université Laval/LOEX, Hôpital Enfant-Jésus, 1401 18e Rue, Québec, QC G1V 0A6, Canada
- Département d’Ophtalmologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
| | - Sylvain Chemtob
- Département d’Ophtalmologie, Faculté de Médecine, Université de Montréal, Montréal, QC H3T 1J4, Canada
| | - Lucie Germain
- Regenerative Medicine Division of the Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada
- Centre de Recherche en Organogénèse Expérimentale de l’Université Laval/LOEX, Hôpital Enfant-Jésus, 1401 18e Rue, Québec, QC G1V 0A6, Canada
- Département de Chirurgie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
| | - Sylvain L. Guérin
- Regenerative Medicine Division of the Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada
- Centre Universitaire d’Ophtalmologie (CUO)-Recherche, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1J 1Z4, Canada
- Centre de Recherche en Organogénèse Expérimentale de l’Université Laval/LOEX, Hôpital Enfant-Jésus, 1401 18e Rue, Québec, QC G1V 0A6, Canada
- Département d’Ophtalmologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
| |
Collapse
|
4
|
Li Q, Wu X, Xin M. Strengthened rebamipide ocular nanoformulation to effectively treat corneal alkali burns in mice through the HMGB1 signaling pathway. Exp Eye Res 2021; 213:108824. [PMID: 34742693 DOI: 10.1016/j.exer.2021.108824] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 10/27/2021] [Accepted: 10/31/2021] [Indexed: 01/12/2023]
Abstract
Corneal alkali burns are a major ophthalmic emergency, as current therapeutic treatments are limited. Novel treatment targets and new potential agents are required to combat this severe ocular injury. Glycyrrhizin and rebamipide (RBM) are both FDA-approved drugs with potential effects against corneal alkali burns, but RBM is limited by its low aqueous solubility and low bioavailability. This study aimed to utilize dipotassium glycyrrhizinate (DG, a dipotassium salt of glycyrrhizin) as a nanocarrier encapsulating RBM to formulate an ophthalmic solution (marked DG-RBM) with strengthened activities to treat corneal alkali burns. Results showed that an easy DG-RBM preparative process generated particles with high encapsulation efficacy and ultra-small micellar size. The solubility of RBM in DG-RBM in aqueous solution was 3.1 × 105-fold enhanced than its free solution. DG-RBM exhibited excellent storage stability. In vitro cytotoxicity, ex vivo conjunctival responses, and rabbit eye tolerance tests showed that DG-RBM possessed good ocular safety profiles. DG-RBM exhibited improved in vivo corneal permeation profiles and demonstrated a strong effect against H2O2-induced oxidative damage, with a significant effect on promoting epithelial wound healing in corneal cells in vitro. As expected, in a mouse model of corneal alkali burns, the topical administration of DG-RBM achieved a strengthened efficacy against alkali burn damages. The mechanism of this therapeutic effect involved regulating high-mobility group box 1 (HMGB1) signaling and its related angiogenic and proinflammatory cytokines. These findings demonstrate the ease of preparing DG-RBM and its great potential as a novel ocular topical formulation to treat corneal alkali burns by regulating HMGB1 signaling.
Collapse
Affiliation(s)
- Qiqi Li
- College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China; Department of Ophthalmology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, 264100, China
| | - Xianggen Wu
- College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China.
| | - Meng Xin
- Department of Ophthalmology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, 264100, China.
| |
Collapse
|
6
|
Li Y, Jin R, Li L, Hsu HH, You IC, Yoon HJ, Yoon KC. Therapeutic Effect of Topical Adiponectin-Derived Short Peptides Compared with Globular Adiponectin in Experimental Dry Eye and Alkali Burn. J Ocul Pharmacol Ther 2019; 36:88-96. [PMID: 31661350 DOI: 10.1089/jop.2018.0131] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Purpose: To evaluate the efficacy of adiponectin (APN)-derived short peptides (ADPs) 355 compared with globular APN in a mouse model of experimental dry eye (EDE) and corneal alkali burn. Methods: EDE and chemical burn were induced in C57BL/6 mice by desiccating stress and application of NaOH, respectively. Eye drops consisting of 0.01% globular APN, 0.01% ADPs, 0.1% ADPs, or balanced salt solution (BSS) were applied. Tear volume, tear film break-up time, and corneal staining scores were measured. Concentrations of interleukin (IL)-1β, interferon (IFN)-γ, IL-6, CXCL-9, and CXCL-10 using multiplex immunobead assay were evaluated, and flow cytometry were performed. Corneal epithelial defects and haze degree were analyzed, and enzyme-linked immunosorbent assay for IL-1β and transforming growth factor (TGF)-β levels were observed. Results: All treatment groups showed an improvement in clinical parameters and CD4+CCR5+ T cell and CD11b+ cell infiltrations in the conjunctiva (all P < 0.05). Both ADPs groups had significantly decreased concentrations of IL-1β, IFN-γ, IL-6, CXCL-9, and CXCL-10 in the conjunctiva than the EDE or BSS group. Significantly improved parameters of epithelial defect, degree of haze, and concentrations of IL-1β and TGF-β were observed in all treatment groups. However, no significant differences were noted in clinical or experimental parameters among treatment groups. Conclusion: Topical ADPs could effectively improve clinical signs and inflammation of ocular surface in the EDE or alkali burn, and its efficacy and potency were similar to those of globular APN.
Collapse
Affiliation(s)
- Ying Li
- Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
| | - Rujun Jin
- Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
| | - Lan Li
- Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
| | - Henry H Hsu
- Allysta Pharmaceuticals, Belmont, California
| | - In Cheon You
- Department of Ophthalmology, Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea
| | - Hyeon Jeong Yoon
- Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
| | - Kyung Chul Yoon
- Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
| |
Collapse
|
8
|
Baradaran-Rafii A, Ashnagar A, Heidari Keshel S, Jabbehdari S, Baradaran-Rafii G. Regression of corneal neovascularization: Adiponectin versus bevacizumab eye drops. Eur J Ophthalmol 2019; 31:78-82. [PMID: 31523981 DOI: 10.1177/1120672119874947] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
PURPOSE Comparing the effect of adiponectin versus bevacizumab in decreasing corneal neovascularization. METHODS This study was conducted on 30 eyes of 30 New Zealand Albino male rabbits. Corneal neovascularization was induced by a single 7-0 silk suture 2 mm long and 1 mm in front of the limbus for 2 weeks. Rabbits were randomly divided into three groups of adiponectin (20 µg/mL), bevacizumab (5 mg/mL) and artificial tears. The treatments continued up to 14 days. RESULTS At the end of 14 days, the average length of vessels in rabbits treated with adiponectin, bevacizumab and control groups decreased from 2.12 ± 0.32 mm to 0.89 ± 0.46 mm (57.68% ± 19.98%) (P < 0.001), 2.30 ± 0.41 mm to 1.30 ± 0.58 mm (42.49% ± 27.17%) (P = 0.048) and from 2.12 ± 0.44 mm to 1.81 ± 0.42 mm (14.81% ± 5.64%) (P = 0.112), respectively. The length of vessels decreased 57.68% ± 19.98% and 42.49% ± 27.17% in adiponectin versus bevacizumab groups, respectively (P = 0.527). The average surface area of vessels in rabbits treated with adiponectin, bevacizumab and control groups reduced from 5.02 ± 1.50 mm2 to 1.40 ± 0.75 mm2 (70.64% ± 17.76%) (P < 0.001) 0.34 ± 1.1 mm2 to 2.80 ± 1.04 mm2 (48.24% ± 19.23%) (P = 0.039) and 5.12 ± 2.92 mm2 to 4.4 ± 2.55 mm2 (14.68% ± 4.19%) (P = 0.117). Mean surface area of vascularization decreased 70.64% ± 17.76% and 48.24% ± 19.23% in adiponectin versus bevacizumab, respectively (P = 0.013). CONCLUSIONS The results of this study suggest that topical adiponectin can decrease recent corneal neovascularization.
Collapse
Affiliation(s)
- Alireza Baradaran-Rafii
- Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Azin Ashnagar
- Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Saeed Heidari Keshel
- Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Sayena Jabbehdari
- Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | | |
Collapse
|